Bacteriophage Compositions for Drug-Resistant Staphylococcus Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet need for more efficient, potent, and specific anti-Staphylococcus aureus (SA) therapies that can circumvent antibiotic resistance, avoid toxic side effects, and maintain the native gut flora, particularly for immune-compromised patients.
Innovation Solution
Development of isolated, purified bacteriophages with specific polynucleotide sequences (SEQ ID NO: 1 and SEQ ID NO: 2) or their variants with at least 90-93% identity, which target and destroy Staphylococcus aureus, including compositions that include multiple bacteriophages resistant to blood complement inactivation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule antibiotics are used to treat Staphylococcus aureus infections, then bacterial infection is suppressed, but antibiotic resistance develops and toxic side effects occur
Solution Approach 1:
The patent employs multiple distinct bacteriophages (at least two different phages) in combination therapy rather than a single antibiotic agent. This segmentation approach targets different bacterial mechanisms simultaneously, making it harder for S. aureus to develop resistance and reducing the toxic side effects associated with high-dose single antibiotic use.
Solution Approach 2:
The patent uses bacteriophages as intermediary agents that specifically infect and lyse S. aureus bacteria. These phages act as mediators between the treatment goal (killing bacteria) and the patient, providing targeted bacterial destruction without the broad-spectrum toxicity of traditional antibiotics. The phages naturally seek out and destroy bacterial cells through their biological mechanism of infection and lysis.
2Reliability
If broad-spectrum antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but native gut flora is disrupted
Solution Approach 1:
The patent employs bacteriophages that exhibit highly specific local action against S. aureus bacteria. Each phage is engineered or selected to recognize and infect specific bacterial surface markers on S. aureus, providing localized and targeted bacterial destruction. This specificity ensures that only the pathogenic S. aureus is affected while the native gut flora remains untouched, as the phages do not recognize or bind to commensal bacterial species.
3Productivity
If high doses of antibiotics are administered to treat severe infections, then bacterial load is reduced, but toxic side effects increase
Solution Approach 1:
The patent utilizes bacteriophages that possess self-service capabilities through their intrinsic biological mechanisms. The phages automatically locate, bind to, infect, and lyse S. aureus bacteria without requiring external enhancement or high dosing. Their self-propelled infection cycle allows them to efficiently clear bacterial loads at lower concentrations compared to antibiotics, reducing toxic side effects while maintaining effective bacterial clearance rates.
Data Source
AI summary
The present disclosure relates to bacteriophages and compositions capable of infecting and killing Staphylococcus, and use of the same for treating Staphylococcus, e.g. Staphylococcus aureus, bacterial infections.